Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
Key Highlights
- ➤Eikon submits FDA IND application for EIK1006 in advanced metastatic prostate cancer
- ➤EIK1006 is a novel androgen receptor antagonist structurally unrelated to lutamide-class antagonists
- ➤EIK1006 targets wild-type and multiple clinically relevant androgen receptor variants
- ➤Eikon reports EIK1006 achieved impressive potency with favorable pharmaceutical properties
Expert Statements
Roger M. Perlmutter, Chief Executive Officer and Board Chair of Eikon Therapeutics
“The submission of an IND for EIK1006 demonstrates once again that Eikon’s advanced imaging platform can permit the identification of truly novel, highly potent, drug candidates through the visualization of individual proteins in living cells.”
Roger M. Perlmutter, Chief Executive Officer and Board Chair of Eikon Therapeutics
“Our ability to prosecute difficult targets has enabled us to optimize EIK1006 across wild type and multiple clinically relevant variants of the androgen receptor, achieving impressive potency while retaining especially favorable pharmaceutical properties.”
Roger M. Perlmutter, Chief Executive Officer and Board Chair of Eikon Therapeutics
“We look forward to evaluating whether these attributes can translate into meaningful clinical benefit for patients with advanced prostate cancer.”
MILLBRAE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate EIK1006 for the treatment of advanced metastatic prostate cancer. EIK1006 is a novel androgen receptor (AR) antagonist that is structurally unrelated to currently available lutamide-class antagonists.
“The submission of an IND for EIK1006 demonstrates once again that Eikon’s advanced imaging platform can permit the identification of truly novel, highly potent, drug candidates through the visualization of individual proteins in living cells,” said Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon. “Our ability to prosecute difficult targets has enabled us to optimize EIK1006 across wild type and multiple clinically relevant variants of the androgen receptor, achieving impressive potency while retaining especially favorable pharmaceutical properties. We look forward to evaluating whether these attributes can translate into meaningful clinical benefit for patients with advanced prostate cancer.”
Get started
Create a free account to read the full story.